A Comparative Confirmatory Study of STN1012600 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Santen

Status and phase: Completed; Phase 3

Conditions: Primary Open Angle Glaucoma, Ocular Hypertension

Treatments: Drug: Latanoprost ophthalmic solution 0.005%; Drug: STN1012600 ophthalmic solution 0.002%

Study type: Interventional

Funder types: Industry

Identifiers

NCT05495061

101260005LT

Details and patient eligibility

About

To investigate whether the IOP lowering efficacy of STN1012600 ophthalmic solution 0.002% is non-inferior to that of latanoprost 0.005% in subjects with POAG or OHT after treatment for 4 weeks.

Enrollment: 325 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 18 years of age or older.
• Diagnosis of POAG or OHT in both eyes, or one eye with POAG and the other with OHT.
• Corrected Visual Acuity of +0.60 logMAR (Decimal visual acuity 0.3) or better in each eye.

Exclusion criteria

• Presence of any active severe external ocular disease, inflammation, or infection of the eye and/or eyelids in either eye.
• History of severe ocular trauma in either eye.
• Any condition that prevents clear visualization of the fundus in either eye.
• Known allergy, hypersensitivity or contraindications to any components of the study medications or other study related procedures/medications.
• History of ocular surgery specifically intended to lower IOP in either eye.
• History of keratorefractive surgery in either eye.
• Females who are pregnant, nursing, or planning a pregnancy.
• Subjects with known or suspected drug or alcohol abuse.
• Participation in other investigational drugs or device clinical trials within 30 days prior to Screening.
• Any decision by the Investigator to terminate a subject in screening or declare any subject ineligible for any sound medical reason.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

325 participants in 2 patient groups

STN1012600 0.002%

Experimental group

Treatment:

Drug: STN1012600 ophthalmic solution 0.002%

Latanoprost 0.005%

Active Comparator group

Treatment:

Drug: Latanoprost ophthalmic solution 0.005%